glp-1 next generation The Race for the Ozempic How are GLP-1 drugs reshaping

Compared with both placebo and liraglutide at 26 weeks, orally bioavailable semaglutide is superior in reducing BW and non-inferior to liraglutide concerning for decreasing HbA1c [21]

GLP-1 Agonists for Obesity in Non-Diabetic Patients: Game Changer or Overhyped

In a cross-sectional multicenter study conducted by JSG-NAFLD, the presence of diabetes is associated with advanced fibrosis in 1365 biopsy-proven NAFLD patients [104]

As the elderly population is highly prone to health issues such as Type 2 diabetes, the growing geriatric population is expected to drive the GLP-1 analogues market during the forecast period